Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.
Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.
复制标题
DOI：
10.1007/s00259-021-05650-3
复制
发表时间：
2022-05
影响因子：
9.1
通讯作者：
Rebersek, Martina
中科院分区：
文献类型：
--
作者：
Hribernik, Nezka;Huff, Daniel T.;Studen, Andrej;Zevnik, Katarina;Klanecek, Zan;Emamekhoo, Hamid;Skalic, Katja;Jeraj, Robert;Rebersek, Martina
关键词：
在接受免疫检查点抑制剂（ICI）的恶性黑色素瘤（MM）患者中开发免疫相关不良事件（irAE）发展的定量分子成像生物标志物，采用18 F-FDG PET/CT成像。 回顾性分析了58例接受抗PD-1或抗CTLA-4 ICI治疗的MM患者的18F-FDG PET/CT图像，以确定irAE的适应症。考虑了最常受irAE影响的三个靶器官：肠、肺和甲状腺。审查患者病历，以确定哪些患者发生了irAE、irAE级别和至irAE诊断的时间。使用卷积神经网络（CNN）分割靶器官，新的定量成像生物标志物-靶器官内18F-FDG摄取的SUV比值（SUVX%）-与临床irAE状态相关。受试者工作特征曲线下面积（AUROC）用于量化irAE检测性能。未发生irAE的患者用于确定靶器官18F-FDG摄取的正常范围。共有31%（18/58）的患者在三个靶器官中发生了irAE：肠（n=6）、肺（n=5）和甲状腺（n=9）。鉴别irAE的最佳指标为肠（SUV 95%，AUROC=0.79）、肺（SUV 95%，AUROC=0.98）和甲状腺（SUV 75%，AUROC=0.88）。irAE检测的最佳截止值为肠（SUV 95%>2.7 g/mL）、肺（SUV 95%>1.7 g/mL）和甲状腺（SUV 75%>2.1 g/mL）。无irAE患者的SUV比值的正常范围（95%置信区间）为肠[1.74，2.86 g/mL]、肺[0.73，1.46 g/mL]和甲状腺[0.86，1.99 g/mL]。irAE受累器官内18F-FDG摄取增加提供了接受ICI的MM患者发生irAE的预测信息，并代表了irAE的潜在定量成像生物标志物。18F-FDG PET/CT可以在临床症状出现之前检测到一些irAE。
To develop quantitative molecular imaging biomarkers of immune-related adverse event (irAE) development in malignant melanoma (MM) patients receiving immune-checkpoint inhibitors (ICI) imaged with 18F-FDG PET/CT. 18F-FDG PET/CT images of 58 MM patients treated with anti-PD-1 or anti-CTLA-4 ICI were retrospectively analyzed for indication of irAE. Three target organs, most commonly affected by irAE, were considered: bowel, lung, and thyroid. Patient charts were reviewed to identify which patients experienced irAE, irAE grade, and time to irAE diagnosis. Target organs were segmented using a convolutional neural network (CNN), and novel quantitative imaging biomarkers — SUV percentiles (SUVX%) of 18F-FDG uptake within the target organs — were correlated with the clinical irAE status. Area under the receiver-operating characteristic curve (AUROC) was used to quantify irAE detection performance. Patients who did not experience irAE were used to establish normal ranges for target organ 18F-FDG uptake. A total of 31% (18/58) patients experienced irAE in the three target organs: bowel (n=6), lung (n=5), and thyroid (n=9). Optimal percentiles for identifying irAE were bowel (SUV95%, AUROC=0.79), lung (SUV95%, AUROC=0.98), and thyroid (SUV75%, AUROC=0.88). Optimal cut-offs for irAE detection were bowel (SUV95%>2.7 g/mL), lung (SUV95%>1.7 g/mL), and thyroid (SUV75%>2.1 g/mL). Normal ranges (95% confidence interval) for the SUV percentiles in patients without irAE were bowel [1.74, 2.86 g/mL], lung [0.73, 1.46 g/mL], and thyroid [0.86, 1.99 g/mL]. Increased 18F-FDG uptake within irAE-affected organs provides predictive information about the development of irAE in MM patients receiving ICI and represents a potential quantitative imaging biomarker for irAE. Some irAE can be detected on 18F-FDG PET/CT well before clinical symptoms appear.
登录
查看更多内容
DOI：
10.1056/nejmoa1003466
发表时间：
2010-08-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hodi FS;O'Day SJ;McDermott DF;Weber RW;Sosman JA;Haanen JB;Gonzalez R;Robert C;Schadendorf D;Hassel JC;Akerley W;van den Eertwegh AJ;Lutzky J;Lorigan P;Vaubel JM;Linette GP;Hogg D;Ottensmeier CH;Lebbé C;Peschel C;Quirt I;Clark JI;Wolchok JD;Weber JS;Tian J;Yellin MJ;Nichol GM;Hoos A;Urba WJ
通讯作者：
Urba WJ
影响因子：
3
作者：
Nelson EK;Piehler B;Eckels J;Rauch A;Bellew M;Hussey P;Ramsay S;Nathe C;Lum K;Krouse K;Stearns D;Connolly B;Skillman T;Igra M
通讯作者：
Igra M
DOI：
10.1016/j.compmedimag.2019.04.005
发表时间：
2019-07-01
影响因子：
5.7
作者：
Taghanaki, Saeid Asgari;Zheng, Yefeng;Hamarneh, Ghassan
通讯作者：
Hamarneh, Ghassan
影响因子：
158.5
作者：
Larkin, J.;Chiarion-Sileni, V.;Wolchok, J. D.
通讯作者：
Wolchok, J. D.
FDG PET/CT评估肿瘤对免疫疗法的反应：关于免疫调节的EANM研讨会的报告和文献近期综述。
DOI：
10.1007/s00259-018-4171-4
发表时间：
2019-01
影响因子：
9.1
作者：
Aide N;Hicks RJ;Le Tourneau C;Lheureux S;Fanti S;Lopci E
通讯作者：
Lopci E